--- type: "Symbol" title: "Dizal Pharmaceutical (688192.SH) — Community Discussions" description: "Community discussions about this stock, including analyst opinions, earnings analysis, and investment strategies from verified financial professionals and active investors." locale: "en" url: "https://longbridge.com/en/quote/688192.SH/topics.md" symbol: "688192.SH" parent: "https://longbridge.com/en/quote/688192.SH.md" count: 7 datetime: "2026-03-10T02:47:19.925Z" locales: - [en](https://longbridge.com/en/quote/688192.SH/topics.md) - [zh-CN](https://longbridge.com/zh-CN/quote/688192.SH/topics.md) - [zh-HK](https://longbridge.com/zh-HK/quote/688192.SH/topics.md) --- # Dizal Pharmaceutical (688192.SH) — Community Discussions ### [Commercialization and R&D are in full swing, Dizal Pharmaceutical ushers in the "singularity moment"](https://longbridge.com/en/topics/33283948.md) - Author: [锦缎研究院](https://longbridge.com/en/profiles/2576456.md) - Datetime: 2025-08-25T01:42:01.000Z - Comments: 0 - Hawking once proposed that at some point in the future, AI will surpass humans and become an incredible existence. This moment is called the "Singularity Moment," which will trigger a qualitat ### [Has Angelalign's 'Chinese Smile' overseas expansion plan succeeded or not?](https://longbridge.com/en/topics/32756415.md) - Author: [港股研究社](https://longbridge.com/en/profiles/3199113.md) - Datetime: 2025-08-08T10:37:12.000Z - Comments: 0 - Has the pharmaceutical and healthcare sector recently exploded? First, Hengrui Pharmaceuticals secured a global cooperation agreement worth up to $12 billion, followed by WuXi AppTec's positive mid-ye ### [Dizal Pharmaceutical completed 1.796 billion yuan refinancing, attracting mainstream institutional investors to strengthen the layout of innovative drug industry chain.](https://longbridge.com/en/topics/29034724.md) - Author: [财见caijian](https://longbridge.com/en/profiles/13190262.md) - Datetime: 2025-04-21T09:51:10.000Z - Comments: 0 - On April 21, 2025, Dizal Pharmaceutical (stock code:$Dizal Pharmaceutical(688192.CN)) announced that the company has completed the share registration and custody procedures for the private placement o ### [The 2.0 era of medical insurance negotiations: 'True innovation' means meeting 'real needs'](https://longbridge.com/en/topics/25902231.md) - Author: [锦缎研究院](https://longbridge.com/en/profiles/2576456.md) - Datetime: 2024-12-06T03:33:06.000Z - Comments: 0 - This article is based on public information and is for informational purposes only, not constituting any investment advice. With the conclusion of the 2024 medical insurance negotiations, China's medi ### [中国自免市场大年即将到来？](https://longbridge.com/en/topics/10562624.md) - Author: [药械Talks](https://longbridge.com/en/profiles/6059509.md) - Datetime: 2023-12-13T12:52:01.000Z - Comments: 0 - 在全球市场，自免领域已诞生不少重磅药物。有机构预测，自免有望成为中国第二大疾病市场。尽管修美乐（阿达木单抗）未能在中国市场复制 “药王” 神话，却给行业带来了明灯式的指引作用。除竞争激烈的 TNF-α抑制剂外，目前有两趟新一代自免创新药 “列车” 供国产药企选择：一趟是 IL 类生物制剂，一趟是 JAK 小分子抑制剂。而这两趟 “列车”，将让中国自免市场驶向商业化大年... ### [Biotech 赛道的 “尖子生”，立起了商业化盈利标杆](https://longbridge.com/en/topics/10517738.md) - Author: [药械Talks](https://longbridge.com/en/profiles/6059509.md) - Datetime: 2023-11-27T10:36:27.000Z - Comments: 0 - 这两年，Biotech 迎来了通过产品销售成功商业化的阶段。商海浮沉，有药物销售成绩出众的，也有已经实现盈利的。但无论其中哪种 Biotech，都得益于建立了强劲的产品壁垒，$Allist(688578.SH) 、$Sinocelltech(688520.SH) 和$Dizal Pharmaceutical(688192.SH) 就是其中较为典型的例子。这些商业化出众的 Biotech“尖子生”， ### [多款产品迎利好，迪哲医药迈入商业化新阶段，能否向 Biopharma 转变？](https://longbridge.com/en/topics/9575948.md) - Author: [药械Talks](https://longbridge.com/en/profiles/6059509.md) - Datetime: 2023-09-02T11:25:40.000Z - Comments: 0 - 近日，在科创板上市的$Dizal Pharmaceutical(688192.SH) 公布了 2023 年上半年业绩：归母净利润亏损 5.14 亿元，同比亏损扩大。作为一家典型的 Biotech，在未有上市产品贡献业绩之前，持续的研发投入必然带来高额亏损。在过去四年半的时间里，迪哲医药累计亏损额达到 29.53 亿元。好在，迪哲医药终于迎来了首款上市产品——舒沃哲（通用名：舒沃替尼），而且是一款同 ## References - [Dizal Pharmaceutical (688192.SH)](https://longbridge.com/en/quote/688192.SH.md) > Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/688192.SH/topics.md) | [繁體中文](https://longbridge.com/zh-HK/quote/688192.SH/topics.md)